“Chris is a visionary leader who combines expertise in AI with experience in drug discovery and development,” said William F. Feehery, Chief Executive Officer. “His leadership has been instrumental in expanding the adoption of AI-powered biosimulation and virtual trials, helping clients achieve greater success in bringing new medicines to patients faster and with greater confidence.
“Biosimulation combined with generative AI and machine learning is redefining how new medicines are discovered and developed, and is speeding timelines, reducing costs, and improving success rates,” said Bouton. “Leading Certara’s technology strategy to build the industry’s most advanced AI and model-informed drug development platform offers a unique opportunity to advance science and deliver better outcomes for patients worldwide.”
Certara（サターラ）について
サターラは、モデリング＆シミュレーション・ソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。製薬、教育機関、規制当局のお客様 2,400人以上、70ヵ国にてサターラの技術やサービスが活用されています。詳細は弊社ホームページをご覧ください。
サターラの問い合わせ先：
Sheila Rocchio
[email protected]
報道機関の皆様：
赤津笑美 (emi.akatsu@certara.com)
[email protected]
